Across TCGA pan-cancer cohorts, PHF2P2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHF2P2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PHF2P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PHF2P2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, COAD, and UCEC are the cancer types where PHF2P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.160	0.610	<.001	33	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.487	.042	4	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PHF2P2 tumor-vs-normal RNA expression · all PHF2P2 data types